Amarantus Bioscience Holdings Inc (AMBS)

[sumotrader]

About Priority Review Voucher:

Developed by the U.S. FDA in 2007, a Priority Review Voucher (“PRV”) is an incentive for companies to invest in new drugs and vaccines for neglected tropical diseases. A Priority Review means that the time it takes the FDA to review a new drug application is reduced. The PRV is transferable and CAN BE SOLD and entitles the bearer to a priority review for ANY PRODUCT. To date, only 3 companies have received a PRV and none have been sold.

I'll see if i can dig up anything further on the FDA website.

AMBS